Levetiracetam Actavis Group (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates synaptic transmission, decreasing excessive neuronal firing that can trigger seizures. The exact downstream pathways are not fully defined, but the effect results in overall reduced seizure susceptibility.

The appropriate levetiracetam dose is individualized by the prescribing clinician based on factors such as the patient’s age, renal function, seizure type, and response to therapy. Dosage adjustments may be necessary for patients with impaired kidney function or when used with interacting medications.

Safety data for levetiracetam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative therapies when possible. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. It is often chosen for its broad spectrum of activity across seizure types and ease of dosing, though individual response varies.

Levetiracetam should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Levetiracetam is administered orally, typically as tablets or oral solution, and may be taken with or without food. The exact dosing schedule—once, twice, or three times daily—is determined by the prescriber based on clinical needs.

Serious risks include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, significant mood changes including depression or suicidal thoughts, and rare blood disorders like neutropenia. Patients should seek immediate medical attention if they experience rash, mood alterations, or signs of infection.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting enzyme‑inducing anticonvulsants without appropriate dose adjustments.